Matt Hunt talks to those players who have been hesitant about working with a solver and explains the purpose of Octopi's new ...

On this date in 1999, Wu-Tang Clan heavyweight Method Man and Def Squad standout Redman joined forces for the release of their first full-length collaborative album, Blackout!, through Def Jam ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...

In a recent Private Equity Law Report article, Dan Oshinsky discussed with PELR the growing use of LP portfolio financing facilities as investors seek alternative sources of liquidity amid a continued ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Many people who face a heightened ...

To submit a legal/professional healthcare question for future consideration, write to the editor at legalcorner@medscape.net (include “Ask the Expert” in subject line). Hi, everyone. I’m Ericka Adler, ...

Elevated levels of lipoprotein(a) above 175 nmol/L is associated with increased cardiovascular risk, especially among patients with existing heart disease, and warrants aggressive treatment to reduce ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...